221 related articles for article (PubMed ID: 30691610)
1. Canine Cutaneous Haemangiosarcoma: Biomarkers and Survival.
Nóbrega DF; Sehaber VF; Madureira R; Bracarense APFRL
J Comp Pathol; 2019 Jan; 166():87-96. PubMed ID: 30691610
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in 94 cases of dermal haemangiosarcoma in dogs treated with surgical excision: 1993-2007*.
Szivek A; Burns RE; Gericota B; Affolter VK; Kent MS; Rodriguez CO; Skorupski KA
Vet Comp Oncol; 2012 Mar; 10(1):65-73. PubMed ID: 22236371
[TBL] [Abstract][Full Text] [Related]
3. Big endothelin-1 as a tumour marker for canine haemangiosarcoma.
Fukumoto S; Miyasho T; Hanazono K; Saida K; Kadosawa T; Iwano H; Uchide T
Vet J; 2015 Jun; 204(3):269-74. PubMed ID: 25920760
[TBL] [Abstract][Full Text] [Related]
4. Serum vascular endothelial growth factor in dogs with haemangiosarcoma and haematoma.
Frenz M; Kaup FJ; Neumann S
Res Vet Sci; 2014 Oct; 97(2):257-62. PubMed ID: 25241388
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Peroxiredoxin 6 Protects Neoplastic Cells against Apoptosis in Canine Haemangiosarcoma.
Anwar Sh; Yanai T; Sakai H
J Comp Pathol; 2016 Jul; 155(1):29-39. PubMed ID: 27306414
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Dowling M; Samuelson J; Fadl-Alla B; Pondenis HC; Byrum M; Barger AM; Fan TM
PLoS One; 2019; 14(1):e0210297. PubMed ID: 30601866
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical analysis of canine haemangioma and haemangiosarcoma.
Sabattini S; Bettini G
J Comp Pathol; 2009; 140(2-3):158-68. PubMed ID: 19091326
[TBL] [Abstract][Full Text] [Related]
8. Correlation Between Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression in Canine and Feline Squamous Cell Carcinomas.
Millanta F; Andreani G; Rocchigiani G; Lorenzi D; Poli A
J Comp Pathol; 2016 May; 154(4):297-303. PubMed ID: 27012907
[TBL] [Abstract][Full Text] [Related]
9. Descriptive analysis of haemangiosarcoma occurrence in dogs enrolled in the Golden Retriever lifetime study.
Hillman A; Swafford B; Delavenne C; Fieten H; Boerkamp K; Tietje K
Vet Comp Oncol; 2023 Dec; 21(4):700-708. PubMed ID: 37635246
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous haemangiosarcoma in a sheep: morphological, histopathological and immunohistochemical observations.
Preziuso S; Taccini E; Rossi G; Braca G; Renzoni G
J Comp Pathol; 2002 Jul; 127(1):72. PubMed ID: 12354548
[TBL] [Abstract][Full Text] [Related]
11. Expression of platelet-derived growth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma.
Asa SA; Murai A; Murakami M; Hoshino Y; Mori T; Maruo K; Khater A; El-Sawak A; el-Aziz EA; Yanai T; Sakai H
Histol Histopathol; 2012 May; 27(5):601-7. PubMed ID: 22419024
[TBL] [Abstract][Full Text] [Related]
12. Canine splenic haemangiosarcoma: influence of metastases, chemotherapy and growth pattern on post-splenectomy survival and expression of angiogenic factors.
Göritz M; Müller K; Krastel D; Staudacher G; Schmidt P; Kühn M; Nickel R; Schoon HA
J Comp Pathol; 2013 Jul; 149(1):30-9. PubMed ID: 23276383
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas.
Al-Dissi AN; Haines DM; Singh B; Kidney BA
J Comp Pathol; 2009 Nov; 141(4):229-36. PubMed ID: 19560781
[TBL] [Abstract][Full Text] [Related]
14. Use of routine histopathology and factor VIII-related antigen/von Willebrand factor immunohistochemistry to differentiate primary hemangiosarcoma of bone from telangiectatic osteosarcoma in 54 dogs.
Giuffrida MA; Bacon NJ; Kamstock DA
Vet Comp Oncol; 2017 Dec; 15(4):1232-1239. PubMed ID: 27507032
[TBL] [Abstract][Full Text] [Related]
15. Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?
Bray JP; Orbell G; Cave N; Munday JS
J Small Anim Pract; 2018 Feb; 59(2):85-91. PubMed ID: 29210452
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of p53 and pp53 Ser
García-Iglesias MJ; Cuevas-Higuera JL; Bastida-Sáenz A; de Garnica-García MG; Polledo L; Perero P; González-Fernández J; Fernández-Martínez B; Pérez-Martínez C
BMC Vet Res; 2020 Jul; 16(1):239. PubMed ID: 32660487
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines.
Witter LE; Gruber EJ; Lean FZ; Stokol T
Am J Vet Res; 2017 Jan; 78(1):69-79. PubMed ID: 28029283
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours.
Anwar Sh; Yanai T; Sakai H
J Comp Pathol; 2015 Nov; 153(4):278-82. PubMed ID: 26286429
[TBL] [Abstract][Full Text] [Related]
19. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome in 20 cases of lingual hemangiosarcoma in dogs: 1996-2011.
Burton JH; Powers BE; Biller BJ
Vet Comp Oncol; 2014 Sep; 12(3):198-204. PubMed ID: 22905712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
